Also known as: Grail, GRAIL
GRAIL is a healthcare company focused on early cancer detection technologies, including the Galleri multi-cancer early detection test. Following its spin-off from Illumina in June 2024, it began regular-way trading on Nasdaq under GRAL. The company is based in Menlo Park, California.
GRAIL's NHS-Galleri trial missed its primary endpoint of reducing combined Stage III and IV cancer diagnoses. However, the trial showed a 26% reduction in Stage IV diagnoses by the third screening round. Results were presented at ASCO 2026, and GRAIL stock fell following the announcement.
Large-cap healthcare stocks such as Johnson & Johnson and CVS Health are viewed as defensive in a slowdown, with beta values of 0.33 and 0.46. Investors can also pursue higher-risk healthcare companies such as Grail and Viking Therapeutics, whose performance depends more on clinical and product milestones.
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
Grail's multi-cancer blood test failed to significantly boost early detection or reduce late-stage diagnoses in a 142,000-person UK trial, raising doubts about regulatory approval and commercial prospects.
